Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Pharma’s $500B patent problem will come in waves — not as a cliff

Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 12 October →